Cantargia receives patent approval in Japan and Mexico
The patent application covers IL1RAP as a target molecule for antibody therapy and leukemia diagnostics. The IL1RAP originates from the research of Prof Thoas Fioretos.
The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).
Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.